SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is drawing significant attention as the community eagerly anticipates pivotal Phase 3 data for its GPS cancer immunotherapy, with CEO comments on potential curative outcomes driving strong speculation of a massive short squeeze. Investors are actively dismissing bearish takes, instead focusing on shattered technical resistance and accumulation signals that point to a major market revaluation or buyout.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is actively discussed amid conflicting reports on the Middle East conflict; bulls eye a "Trump pump" after claims of the war being "pretty much done," while bears highlight rising oil prices and Iranian denials, fueling concerns of manipulation and a market reversal.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending following multiple analyst upgrades with significantly higher price targets and anticipation around management's comments on stabilizing the BetterHelp segment and addressing debt. The community is actively debating its extreme undervaluation compared to sector peers and its strong free cash flow, fueling speculation of a potential short squeeze amid optimism for its global virtual care platform and AI initiatives.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following a substantial Q4 earnings beat, driven by strong MIPLYFFA sales, which has sparked widespread community optimism about the company's shift to profitability and its undervalued status, with many anticipating further upside from upcoming European approval.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending due to investor concerns over a recently announced convertible senior notes offering, which has sparked questions about potential dilution and management's confidence despite a strong cash position. This comes amidst ongoing community speculation regarding a potential buyout and anticipation for accelerating sales of its gene therapy, Casgevy, and future pipeline updates.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is heavily discussed ahead of its earnings report, with investor sentiment torn between the potential of its AI infrastructure and cloud growth, versus significant concerns over its substantial debt load and capital expenditures, particularly after recent developments around its data center partnerships.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending amidst community discussion surrounding a recent deadline for submitting crucial Full Self-Driving data to NHTSA, which many believe will impact the stock's "autonomy premium" and regulatory outlook. This comes as the company faces a series of executive departures, adding to investor scrutiny of its valuation and market position against intensifying EV competition.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is actively discussed following an analyst upgrade highlighting strong demand for its upcoming R2, which is set for a highly anticipated unveiling on March 12. This event is fueling community excitement and debate over its transformative potential and pricing amidst rising oil costs.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas (ONDS) is actively discussed after announcing a merger with U.S. defense prime contractor Mistral Inc., a move many view as a transformative step providing direct access to significant Department of Defense programs and expanding its role in the autonomous defense market. While bulls are enthusiastic about this strategic positioning, community dialogue also reflects concerns regarding potential share dilution from the all-stock deal and its immediate impact on stock performance ahead of upcoming earnings.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending as its co-founders establish a new mRNA innovations company and Pfizer reportedly sells its stake, fueling community debate over the company's strategic pivot to its robust oncology pipeline, backed by significant cash reserves, amidst broader market skepticism about mRNA technology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nyxoah SA (NASDAQ:NYXH) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Nyxoah SA (NASDAQ:NYXH - Get Free Report) have received an average rating of "Moderate Buy" from the five analysts that are currently covering the firm, MarketBeat Ratings reports. One...

Cantor Fitzgerald Upgrades Nyxoah (NASDAQ:NYXH) to "Strong-Buy"

Cantor Fitzgerald upgraded Nyxoah to a "strong-buy" rating in a research report on Wednesday...

Nyxoah (NYXH) Expected to Announce Earnings on Thursday

Nyxoah (NASDAQ:NYXH) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 12. (View Earnings Report at...

Veeva Systems (VEEV) Q4 Earnings and Revenues Surpass Estimates

Veeva (VEEV) delivered earnings and revenue surprises of +7.17% and +3.35%, respectively, for the quarter ended January 2026. Do the numbers hold clues to what lies ahead for the stock?

Nyxoah SA (NASDAQ:NYXH) Short Interest Down 17.8% in February

Nyxoah SA (NASDAQ:NYXH - Get Free Report) was the recipient of a significant drop in short interest in February. As of February 13th, there was short interest totaling 237,379 shares, a drop of 17.8...

Nyxoah SA (NASDAQ:NYXH) Short Interest Update

Nyxoah SA (NASDAQ:NYXH - Get Free Report) was the target of a significant increase in short interest in January. As of January 30th, there was short interest totaling 288,814 shares, an increase of...

Nyxoah (NASDAQ:NYXH) Trading Down 2.9% - Here's What Happened

Nyxoah (NASDAQ:NYXH) Shares Down 2.9% - Should You Sell...

Nyxoah Gains Favorable CMS Reimbursement Ruling for Genio System

Nyxoah secures a finalized CMS rule that sharply lifts 2026 reimbursement for Genio implants, opening fresh momentum for its OSA therapy.

<ul class="summary-bullets"><li>Under the new rule, Hospital Outpatient Department (HOPD) reimbursement for Nyxoah’s Genio hypoglossal nerve stimulation implants will increase to approximately $45,000 starting in 2026.</li><li>According to Nyxoah, the Genio procedure is well-suited for the ASC environment, and the new rules create new opportunities for site-of-service diversification as well.</li></ul><p>Shares of Nyxoah SA (NYXH) jumped 7% in the pre-market session on Wednesday after the company said that its Genio Therapy would benefit from the new medicare reimbursement criteria for CY2026.</p><p>The U.S. Centers for Medicare &amp; Medicaid Services (CMS) finalized its CY2026 medicare reimbursement rules on Friday.</p><h2 class="st-heading-2">How Will It Aid Nyxoah?</h2><p>Under the new rule, Hospital Outpatient Department (HOPD) reimbursement for Nyxoah’s Genio hypoglossal nerve stimulation implants for the treatment of Obstructive Sleep Apnea will increase to approximately $45,000 starting in 2026, a 48% rise compared to 2025, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/26/3194857/0/en/Nyxoah-s-Genio-Therapy-Receives-Significant-2026-Medicare-Reimbursement-Increases-Under-Final-CMS-Rule.html">said</a>. Ambulatory Surgery Centers (ASC) facility reimbursement, meanwhile, will increase to $42,373, reflecting a 58% increase compared to 2025.</p><p>Nyxoah expects the stronger reimbursement framework to support broader adoption, increase procedural throughput, and expand across Medicare-heavy institutions. Further, the procedure is well-suited for the ASC environment, and the change in rules creates new opportunities for therapy expansion and site-of-service diversification, the company added.</p><h2 class="st-heading-2">Others To Benefit From New Rules</h2><p>The new rules apply to Nyxoah’s peers, too. Earlier this week, Stifel analyst Jonathan Block upgraded Inspire Medical Systems (INSP) to ‘Buy’ from ‘Hold’ while also hiking the price target to $110, up from $100.</p><p>Inspire Medical makes the Inspire V implant to treat obstructive sleep apnea. It is installed in an approximate 60-minute outpatient procedure. According to the Stifel analyst, the company's headwinds are easing following CMS's positive reimbursement revision on Friday.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around NYXH fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’ levels.</p><figure class="image"><img style="aspect-ratio:624/60;" src="data:image/png;base64,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" width="624" height="60" alt="NYXH’s Sentiment Meter and Message Volume as of 7:56 a.m. ET on Nov. 26, 2025 | Source: Stocktwits"><figcaption>NYXH’s Sentiment Meter and Message Volume as of 7:56 a.m. ET on Nov. 26, 2025 | Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/NYXH">NYXH stock</a> fell 43% this year and by about 44% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/bytedance-reportedly-tops-chinese-nvidia-chip-buyers-but-now-it-can-t-use-them/cL53FkSREWe">Bytedance Reportedly Tops Chinese Nvidia Chip Buyers – But Now It Can't Use Them</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Natalie Boller, 63, has a Genio Nyxoah bilateral hypoglossal nerve stimulator implant fitted for obstructive sleep apnoea. Picture date: Wednesday December 4, 2024. (Photo by Lucy North/PA Images via Getty Images)

Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy

Nyxoah expects the stronger reimbursement framework to support broader adoption, increase procedural throughput, and expand across Medicare-heavy institutions.

Equity

Cantor Fitzgerald Raises Earnings Estimates for Nyxoah

Nyxoah SA (NASDAQ:NYXH - Free Report) - Research analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of Nyxoah in a report released on Wednesday, November 19th. Cantor...

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.

NYXH
Nyxoah SA

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NYXH News

NYXHNyxoah SA